Physician profile
Terence Conrad Ross
NPI 1154311926
$5,571.48
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $465 · 2021: $828 · 2022: $561 · 2023: $1,555 · 2024: $1,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,850 · Travel and Lodging: $1,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,849.56 |
| Travel and Lodging | $1,335.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,502.65 | 2019-2024 | Aveir, Ensite Precision, Tendril |
| Boston Scientific Corporation | $390.51 | 2022-2024 | Watchman Access System, Bodyguardian |
| Atricure, INC. | $336.04 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $323.06 | 2019-2023 | Xarelto |
| Biosense Webster, INC. | $245.91 | 2019-2021 | |
| Pfizer INC. | $237.03 | 2020-2024 | |
| Philips North America LLC | $208.09 | 2019-2024 | (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und |
| Medtronic, INC. | $185.09 | 2021-2023 | Na |
| Merck Sharp & Dohme LLC | $168.53 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $159.72 | 2022-2024 | |
| Amgen INC. | $150.27 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $115.39 | 2019-2023 | Lifevest |
| Medtronic Vascular, INC. | $93.67 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $93.50 | 2019-2024 | |
| Cardiva Medical, INC. | $64.27 | 2023-2024 | Cardiva Vascade Mvp Vvcs 6-12f |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $53.50 | 2021-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.25 | 2020-2023 | Jardiance |
| Lundbeck LLC | $27.83 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $22.60 | 2019 | |
| Esperion Therapeutics, INC. | $20.66 | 2024 | Nexletol |
| Impulse Dynamics (USA) INC. | $19.89 | 2023 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $19.08 | 2023 | Brilinta |
| Acutus Medical, INC. | $17.83 | 2023 | |
| Angiodynamics, INC. | $17.67 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $17.16 | 2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $13.81 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.99 | 2021 | |
| Astellas Pharma US INC | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terence Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.